Company / R&D Expense
Ceribell, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$19.1M
FY2025
5-year range
$9.0M / $19.1M
FY2023-FY2025
Trend
+112.8%
vs FY2024
Sector context
#98 of 110
Health Care
What the data says
Ceribell, Inc.'s r&d expense of $19M is lower than 89% of companies in the Health Care sector (FY2025). Improved from $9M to $19M over the past 2 years.
Based on SEC 10-K filings.
$19M in FY2025.
Improved from $9M to $19M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 110This company $19.1M Sector average $298.2M
▼
-93.6% below sector average
Key checks
Key Insights
- In FY2025, r&d expense increased 112.8% year-over-year.
- Ranks #98 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.1M | +112.8% |
| FY2024 | $9.0M | +0.0% |
| FY2023 | $9.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026